Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWE2N4)

• Drug Name: Auranofin Drug Info
• Synonyms: Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory arthritis	FA2Z	Approved	[1]

• Therapeutic Class: Antirheumatic Agents
• Cross-matching ID:
  PubChem CID: 24199313
  CAS Number: CAS 34031-32-8
  TTD Drug ID: DMWE2N4
  VARIDT Drug ID: DR01329
  ACDINA Drug ID: D00051

Molecule-Related Drug Atlas

Drug(s) Targeting Steroid hormone receptor ERR (ESRR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cortisone Acetate	DMG8K57	Acne vulgaris	ED80	Approved	[2]
Beclomethasone	DMZPHIK	Allergic rhinitis	CA08.0	Approved	[2]
Loteprednol Etabonate	DM8QTJI	Eye inflammation	9A02	Approved	[2]
Desonide	DMTP2NJ	Allergic rhinitis	CA08.0	Approved	[2]
Fluocinonide	DM65KL8	Exanthem		Approved	[2]
Medrysone	DMJ90O5	Corneal abrasion	NA06.4	Approved	[2]
Halcinonide	DMGLAX1	Exanthem		Approved	[2]
Amcinonide	DMM1JL9	Exanthem		Approved	[2]
Prednicarbate	DMBUNVW	Exanthem		Approved	[2]
Flurandrenolide	DMHCI9S	Exanthem		Approved	[2]

Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[5]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[6]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[5]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[5]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[7]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[5]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[5]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[8]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[9]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[10]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[11]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[12]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[14]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[15]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[16]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[17]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[18]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[19]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[20]

Drug(s) Affected By Metallothionein-1A (MT1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[21]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[22]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[26]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[22]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[22]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Steroid hormone receptor ERR (ESRR)	TTP3UTW	ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN	Modulator	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[3]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Metallothionein-1A (MT1A)	OTKBH52X	MT1A_HUMAN	Drug Response	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6306).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
• [4] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [5] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
• [6] Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
• [7] Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
• [8] Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
• [9] Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
• [10] FDA Drug Development and Drug Interactions
• [11] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [12] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [13] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [14] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [15] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [16] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [17] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [18] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [19] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [20] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [21] Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. Anticancer Res. 2003 Jan-Feb;23(1A):299-303.
• [22] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [23] Arsenic trioxide (ATO) influences the gene expression of metallothioneins in human glioblastoma cells. Biol Trace Elem Res. 2012 Dec;149(3):331-9.
• [24] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [27] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [28] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.